Skip to content

A clinical study of AP Enzymatically Hydrolyzed Collagen Peptides to assess skin health improvement and safety evaluation (random allocation, double-blind, placebo control)

A clinical study of AP Enzymatically Hydrolyzed Collagen Peptides to assess skin health improvement and safety evaluation (random allocation, double-blind, placebo control)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0007836
Enrollment
60
Registered
2022-10-21
Start date
2021-10-28
Completion date
Unknown
Last updated
2022-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : not containing AP Enzymatically Hydrolyzed Collagen Peptides Take 3 pills, once a day at evening.

Sponsors

P&K Skin Research Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: • Subjects whose crow’s feet grade is above 3 on visual evaluation • Subjects who have signed consent form voluntarily after being informed well of object of study and all related contents

Exclusion criteria

Exclusion criteria: • Subjects who are now suffering or in the treatment of skin illness such as atopic dermatitis, psoriasis, etc. • Subjects who are sensitive or have allegic to food related to test food • Subjects who have spots, acne, erythema, capillary dilatation or hypersensitive skin at test area • Subjects who had facial treatment (skin peeling, chemical curling, and other skin care) within 1 month or had botox, fillers and etc. on the face within 6 months from visit 1 • Subjects who had used skin cream which contains steroid on the face or consumed oral retinoids/steroids within 3 months from visit 1 • Subjects who used functional cosmetics for wrinkle improvement (retinoids, retinol, AHA), hyper-moisturizing cosmetics or skin-care device (LED mask, ion-booster, etc.) within 2 weeks from visit 1 • Subjects who consumed diet pills (absorption inhibitor, antidepressant, appetite suppressant and etc.), contraceptive or hormone drug and diuretic within 1 month from visit 1 • Subjects who consumed health functional food which contains antioxidants, hyaluronic acid and collagen, EPO, and medicine or health functional food which contains Vitamin A, C and E. • Subjects who had or planning to participate in other interventinal clinical test (including human clinical test) within 1 month from visit 1 • Subjects who is diagnosed and having treatment of uncontrollable chronic disease such as hypertension (systolic blood pressure greater than 160 mmHg or diastolic blood pressure greater than 100 mmHg, measured After 10 minutes of stabilization), diabetic with uncontrolled blood sugar (not less than 180 mg/dl of fasting blood sugar), asthma and etc. • Subjects who have mental illness such as schizophrenia, depression, drug addiction and etc. • Subjects who are pregnant, breast-feeding or have possibility of being pregnant within 3 months or who refuse to sign at contraception • Subjects who are hospitalized, treated with medication, or rehabilitation for alcohol use/induced disorders, heart disease, central nervous disorder, etc. through medical history investigation, etc • Subjects who smoke or have not been smoking for more than 1 year • Any subjects who are considered to be inappropriate to participate in the study by the researcher.

Design outcomes

Primary

MeasureTime frame
Measurement of crow’s feet, Measurement of marionette wrinkle;Measurement of skin elasticity;Measurement of skin density/thickness;Measurement of skin roughness; Measurement of facial (cheek) lifting

Secondary

MeasureTime frame
Physical examination;Measurement of vital sign

Countries

Korea, Republic of

Contacts

Public Contactareum kim

P&K Skin Research Center

alzlapfdhd11@naver.com+82-2-6925-1501

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026